Shalaparny (Desmodium gangeticum)

Desmodium gangeticum, known in Ayurveda as Shalaparny, is a leguminous herb whose primary bioactive compound gangetin exerts anti-inflammatory effects by inhibiting pro-inflammatory mediators and modulating immune pathways. It is classified among the Dashamoola group of Ayurvedic roots and has been used traditionally for pain relief, fever, and respiratory conditions.

Origin & History

Shalaparni is derived from the dried roots of Desmodium gangeticum, a leguminous herb native to the Indian subcontinent belonging to the Fabaceae family. The roots are processed through traditional drying and grinding methods or modern solvent extraction using ethanol, hydroalcohol, or chloroform to obtain bioactive compounds.

Historical & Cultural Context

Shalaparni is a key ingredient in traditional Ayurvedic medicine, historically used as part of the Dashmoola (ten roots) formulation and in classical preparations including Chyavanprash and Dashmoolarishtha. In Ayurveda, it has been traditionally indicated for fever, respiratory conditions, diarrhea, parasitic infections, and cough.

Health Benefits

• Anti-inflammatory properties through the compound gangetin (Traditional evidence only)
• Analgesic (pain-relieving) effects (Traditional evidence only)
• Antimicrobial activity against bacteria and fungi (Traditional evidence only)
• Antioxidant support for immune function (Traditional evidence only)
• CNS depressant properties for potential calming effects (Traditional evidence only)

How It Works

Gangetin, a pterocarpan flavonoid isolated from Desmodium gangeticum root, inhibits cyclooxygenase (COX) enzymes and suppresses NF-κB signaling, reducing the synthesis of pro-inflammatory prostaglandins and cytokines such as TNF-α and IL-6. The plant's alkaloids, including hordenine and salsolidine, contribute to analgesic activity by modulating opioid-receptor-adjacent pathways and dampening peripheral pain sensitization. Antioxidant activity is attributed to polyphenolic constituents that scavenge reactive oxygen species (ROS) and upregulate endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase.

Scientific Research

The available research lacks human clinical trials, randomized controlled trials, or meta-analyses documenting efficacy. Current literature focuses primarily on pharmacognostical characterization and phytochemical composition rather than clinical outcomes.

Clinical Summary

Current evidence for Desmodium gangeticum is almost entirely preclinical and rooted in traditional Ayurvedic use, with no large-scale randomized controlled trials published in peer-reviewed literature as of 2024. In vitro studies have demonstrated antimicrobial activity of root extracts against Staphylococcus aureus and Candida albicans at minimum inhibitory concentrations (MIC) of 125–250 µg/mL, and rodent models have shown statistically significant reductions in carrageenan-induced paw edema comparable to standard anti-inflammatory drugs at doses of 200–400 mg/kg body weight. A small number of Ayurvedic clinical case series report its use in formulations for vata-related disorders and fever, but these lack control groups, blinding, or standardized outcome measures. Overall, the evidence base is insufficient to establish efficacy in humans, and clinical trials are needed before definitive therapeutic claims can be made.

Nutritional Profile

Shalaparny (Desmodium gangeticum) is a medicinal herb primarily valued for its bioactive phytochemical composition rather than macronutrient density. Macronutrient data from standardized nutritional analysis is limited, but the plant material (roots, leaves, stems) contains moderate crude fiber (estimated 15–25% dry weight in root material), moderate protein content (approximately 8–14% dry weight in leaf material, containing amino acids including tryptamine derivatives), and low fat content (<3% dry weight). Key bioactive compounds include: (1) Alkaloids — gangetin (a pterocarpan-type isoflavonoid), desmodin, and viscosin, with gangetin being the primary pharmacologically active constituent concentrated in root bark; (2) Flavonoids — vitexin, orientin, and isovitexin, present in leaves and stems; (3) Pterocarpans — gangetin, gangetinin, and desmocarpin identified in root extracts; (4) Phenolic acids — caffeic acid and ferulic acid derivatives contributing to antioxidant activity; (5) Saponins — present in moderate concentrations in root material; (6) Tryptamine and hypaphorine alkaloids detected in root extracts. Mineral content includes calcium, iron, and potassium at levels typical of leguminous herbs, though precise concentrations lack modern quantification. Bioavailability note: Gangetin and related pterocarpans are lipophilic and may have enhanced absorption with fat-containing food; flavonoid glycosides (vitexin, orientin) show moderate oral bioavailability with gut microbiota-dependent metabolism. Most compositional data derives from phytochemical screening studies rather than standardized nutritional assays.

Preparation & Dosage

No clinically studied dosage ranges are available from the research provided. Traditional Ayurvedic dosing information is not detailed in the available sources. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Dashmoola herbs, Ashwagandha, Turmeric, Boswellia, Ginger

Safety & Interactions

Desmodium gangeticum has a long history of use in Ayurvedic medicine with no widely documented severe adverse effects at traditional doses, but systematic safety data in humans are lacking. Because gangetin and related compounds inhibit COX enzymes, concurrent use with NSAIDs, aspirin, or anticoagulants such as warfarin may theoretically potentiate bleeding risk or gastrointestinal irritation. The herb is contraindicated in pregnancy in traditional systems due to its reported uterotonic properties, and breastfeeding women should avoid use due to insufficient safety data. Individuals with autoimmune conditions or those on immunosuppressive therapy should consult a healthcare provider before use, as immune-modulating activity could interfere with treatment.